Phase II trial of retroperitoneal lymph node dissection as first-line treatment for testicular seminoma with isolated retroperitoneal disease (1-2cm)
The purpose of this study is to evaluate the safety and effectiveness of Retroperitoneal Lymph Node Dissection (RPLND) as a treatment option for seminoma that has gone to the lymph nodes in the retroperitoneum.
This phase II trial studies how well retroperitoneal lymph node dissection (RPLND) works in treating patients with stage I-IIa testicular seminoma. The retroperitoneum is the space in the body behind the intestines that is typically the first place that seminoma spreads. RPLND is a surgery that removes lymph nodes in this area to treat testicular seminoma and may experience fewer long-term toxicities, such as a second cancer, cardiovascular disease, metabolic syndrome (pre-diabetes), or lung disease.
- IRB Number: 1601564086 (4T-14-1)
- Research Study Identifier: TX5915
- Principal Investigator: Clint Cary, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required